PEG DOXOZEST 20MG ING

About

Pegylated liposomal doxorubicin is an anthracycline topoisomerase inhibitor encapsulated in stealth liposomes, which are coated with polyethylene glycol (PEG). This innovative formulation significantly alters the pharmacokinetic profile of doxorubicin, allowing for prolonged circulation time and enhanced accumulation in tumor tissues through the enhanced permeability and retention (EPR) effect, while reducing exposure to healthy tissues, particularly the heart. Doxorubicin itself exerts its cytotoxic effects by intercalating into DNA, inhibiting topoisomerase II, and generating free radicals, leading to DNA damage and apoptosis in rapidly dividing cancer cells. The liposomal encapsulation helps to mitigate common dose-limiting toxicities such as cardiotoxicity and myelosuppression, making it a valuable option for treating various solid tumors and hematologic malignancies, especially in patients where conventional doxorubicin might be too toxic.

Uses

• Treatment of ovarian cancer, particularly in platinum-resistant disease.
• Management of AIDS-related Kaposi's sarcoma.
• Treatment of multiple myeloma in combination with bortezomib.
• Used in metastatic breast cancer after failure of other therapies.

Directions For Use

Administer intravenously as an infusion over 30-90 minutes, typically every 3-4 weeks, as prescribed by an oncologist.

Benefits

• Reduced cardiotoxicity compared to conventional doxorubicin.
• Prolonged circulation time and enhanced tumor accumulation.
• Lower incidence of myelosuppression and alopecia.
• Effective in treating various solid tumors and hematologic malignancies.
• Improved safety profile for certain patient populations.
• Allows for continued treatment in patients intolerant to conventional doxorubicin.

Side Effects

• Palmar-plantar erythrodysesthesia (PPE)
• Nausea and vomiting
• Stomatitis/mucositis
• Myelosuppression (neutropenia, thrombocytopenia)
• Fatigue
• Alopecia (less common than conventional doxorubicin)
• Infusion-related reactions
• Cardiotoxicity (reduced but still possible)
• Diarrhea
• Constipation
• Skin rash
• Anemia

Safety Measures

• Alcohol - Avoid alcohol due to potential for increased liver toxicity and exacerbation of gastrointestinal side effects.
• Pregnancy - Contraindicated during pregnancy due to significant risk of fetal harm. Effective contraception is essential.
• Breastfeeding - Discontinue breastfeeding during treatment and for a period after the last dose due to potential for serious adverse reactions in the infant.
• Liver - Dose adjustment may be necessary in patients with hepatic impairment; monitor liver function closely.
• Kidney - No specific dose adjustment is typically required for mild to moderate renal impairment, but monitor for toxicity.
• Lung - Monitor for signs of pulmonary toxicity, including pneumonitis, especially in patients with pre-existing lung conditions or prior radiation therapy.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.